Clinical Trial Update: Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating inhaled iloprost for sarcoidosis-associated pulmonary hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension
• Sarcoidosis

Drugs mentioned

• Iloprost (iloprost)

Snippet

Sponsor: University of Cincinnati | Conditions: Sarcoidosis, Pulmonary Arterial Hypertension | Phase 4 | Status: COMPLETED